JLK Secures US Patent for AI Cerebrovascular Disease Analysis Technology... Accelerates Global Market Expansion

JLK, a medical artificial intelligence (AI) specialist company led by CEO Kim Dongmin, announced on August 20 that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its AI cerebrovascular disease analysis technology.

With the acquisition of this patent, JLK has been recognized for its achievements in global regulatory approvals, further establishing its global technological competitiveness both domestically and internationally. Currently holding seven FDA approvals in the United States, JLK plans to accelerate its entry into the US healthcare market following this patent approval.

The US patent, which has now been approved for registration, covers three core technologies: a cerebrovascular disease learning device, a cerebrovascular disease detection device, and methods for learning and detecting cerebrovascular diseases. The patent centers on a multi-stage lesion detection and learning technology that integrates CNN (Convolutional Neural Network) and RNN (Recurrent Neural Network) based on 3D TOF MRA (three-dimensional time-of-flight magnetic resonance angiography) imaging.

In terms of lesion detection devices and methodologies, JLK has implemented MIP MRA (Maximum Intensity Projection) and developed a technical workflow that sequentially learns and detects spatial features, inter-frame characteristics, and lesion features. This has significantly improved the accuracy of early diagnosis for cerebrovascular diseases such as stroke.

Notably, JLK has secured exclusive rights to a complex neural network architecture that organically combines a CNN-based spatial feature learning model, an RNN-based frame analysis model, and a lesion detection CNN model. This has positioned the company as a leader over similar technologies in the United States.

According to the company's semi-annual report, sales in the second quarter of this year increased by 120% compared to the first quarter. The main drivers were the expanded distribution of solutions to domestic medical institutions and the increased use of the AI stroke diagnosis solution in clinical settings. The company also maintains a stable financial structure, holding sufficient liquid assets such as cash and cash equivalents to ensure steady operations.

Kim Dongmin, CEO of JLK, stated, "This US patent proves that our AI technology for cerebrovascular disease analysis is world-class," adding, "It will serve as a key asset not only for the US market but also for our global market strategy." He further noted, "We expect this patent to provide an important foundation for expanding the supply of our solutions and establishing partnerships with hospitals and medical institutions in the United States in the future."

This content was produced with the assistance of AI translation services.